



## **Scopus BioPharma to Present at the LD Micro Main Event**

*Scopus to present on the recent launch of Duet Therapeutics,  
its wholly-owned subsidiary focused on immuno-oncology*

*Presentation to include a discussion of preclinical data released at  
the 17<sup>th</sup> Annual Meeting of the Oligonucleotide Therapeutics Society*

**New York, New York, October 5, 2021** – [Scopus BioPharma Inc.](#) (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced it will be presenting at the LD Micro Main Event, which is being held in-person and virtually from October 12<sup>th</sup> through 14<sup>th</sup>, 2021.

The company will present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology, which Scopus announced in September 2021.

Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting in-person on behalf of the company. Dr. Horsager’s presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11:00 AM Eastern Time / 8:00 AM Pacific Time at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website. Management will be available for one-on-one meetings to be held throughout the conference.

Investors interested in attending the conference in-person or virtually can register [here](#). Once registered, you can request one-on-one meetings with the company through the conference website.

Dr. Horsager recently presented at the 17<sup>th</sup> Annual Meeting of the Oligonucleotide Therapeutics Society during which he discussed data from two different studies that suggest that DUET-01 and DUET-02, two of Duet’s unique bifunctional oligonucleotides, can expand the reach and efficacy of cancer immunotherapies beyond certain standard-of-care treatments.

As previously announced, Scopus will also be presenting at The MicroCap Rodeo’s Fall Harvest Best Ideas Conference on Wednesday, October 6, 2021 at 5:00 PM Eastern Time. Investors interested in attending the virtual conference can register [here](#).

### **About LD Micro Main Event**

The 2021 LD Micro Main Event (XIV) will be held at the Luxe Sunset Bel-Air in Los Angeles from October 12<sup>th</sup> through 14<sup>th</sup>, 2021. The festivities run from 8:00 AM Pacific Time through 5:30

PM Pacific Time on October 12<sup>th</sup> and 13<sup>th</sup> with a morning session on October 14<sup>th</sup>. This three-day, investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in-person. For more information, please contact [dean@ldmicro.com](mailto:dean@ldmicro.com).

### **About the *Duet Platform***

Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the *Duet Platform*. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

The *Duet Platform* is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

- RNA silencing CpG-STAT3siRNA (“*DUET-01*”)
- Antisense CpG-STAT3ASO (“*DUET-02*”)
- DNA-binding inhibitor CpG-STAT3decoy (“*DUET-03*”)

DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

### **About Scopus BioPharma**

Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The company’s lead drug candidate is a novel, targeted immunoncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. Additional STAT3-targeting immunotherapy drug candidates include bifunctional antisense and DNA-binding inhibition therapies. In addition, the company is developing additional drug candidates that target the endocannabinoid system, including MRI-1867 for the treatment systemic sclerosis. The company also seeks to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Receive updates by following Scopus BioPharma on Twitter [here](#).

### **Forward-Looking Statements**

This press release may include forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the company’s Form 10-K for the fiscal year ended December 31, 2020, as amended, filed with the U.S. Securities and Exchange Commission (“SEC”)) and uncertainties which could cause actual results to differ from the

forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Further, there can be no assurance that the company will identify and/or consummate any transaction relating to any additional technologies.

## **Contacts**

Rodd Leeds/David Waldman  
Crescendo Communications, LLC  
Tel: (212) 671-1020  
Email: SCPS@crescendo-ir.com

Hugh Burns/Delia Cannan/Nicholas Leasure  
Reevemark  
Tel: (212) 433-4600  
Email: scopus@reevemark.com